

RECEIVED  
SECRETARY OF THE SENATE Go to F  
PUBLIC RECORDS

05 AUG 29 AM 4:06

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name  
 Organization Sanofi-Synthelabo Inc. and Aventis Pharmaceuticals Inc., members of the sanofi-aventis Group

2. Address  Check if different than previously reported  
 Address 300 Somerset Corporate Center Mail Stop SCC3-2-0852  
 City Bridgewater State NJ Zip Code 08807 Country USA

3. Principal place of business (if different than line 2)  
 City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_  
 State/Zip or Country \_\_\_\_\_

4a. Contact Name Prefix Ms. Full Name Elise Rhodes b. Telephone number 908-243-4379 c. E-mail \_\_\_\_\_

5. Senate ID # 56838-12

7. Client Name  Self \_\_\_\_\_

6. House ID # 35186000

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30)  OR Year End (July 1-December 3)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇒ Termination Date \_\_\_\_\_

11. No Lobbying Activi

## INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>1,480,699</u></p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expens accounting method. See instructions for description of option:</p> <p><input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(8) of Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Revenue Code</p>
--	--

Form Com

Printed Name and Title Elise Rhodes, Sr. Director, State Government Affairs

1000452908



Registrant Name \_\_\_\_\_

Client Name Sanofi-Synthelabo Inc. and Aventis Pharmaceutica  
members of the sanofi-aventis Group

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue >

Medicaid Reform proposals that impact the pharmacy benefit under the Medicaid program.

17. House(s) of Congress and Federal agencies contacted  Check if None

US House of Representatives  
US Senate

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for this issue

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Eddie	Evans		N/A
Ann	Taylor		N/A
Saira	Sultan		N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Sanofi-aventis is a corporation under French Commercial law, headquartered in Paris, France. Sanofi-Synthelabo and Aventis Pharmaceuticals Inc. are US affiliates and members of the sanofi-aventis group. The sanofi-aventis interest in this issue is to protect access and coverage of the pharmaceutical benefit to the Medicaid population.

0000452909



Printed Name and Title Elise Rhodes, Sr. Director, State Government Affairs



Registrant Name sanofi-aventis group

Client Name Sanofi-Synthelabo Inc. and Aventis Pharmaceutical members of the sanofi-aventis Group

(formerly known as Aventis Pharmaceuticals and Sanofi-Synthelabo)

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code PHA - Pharmacy (one per page)

16. Specific lobbying issues *Add page to continue specific issues description for this issue*

Discussions related to Congressional intent of the Veterans Healthcare Act of 1994 and the TRICARE program regarding the provisions related to reimbursement for prescription drugs.

17. House(s) of Congress and Federal agencies contacted  Check if None  
U.S. Senate  
U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Richard	Hodge		N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Sanofi-aventis is a corporation under French Commercial law, headquartered in Paris, France. Sanofi-Synthelabo and Aventis Pharmaceuticals Inc. are US affiliates and members of the sanofi-aventis Group. The sanofi-aventis Group's interest in this issue is to protect access and coverage of the pharmaceutical benefit to the Veterans and TRICARE population.

Printed Name and Title \_\_\_\_\_

0000452910



1

Registrant Name sanofi-aventis group Client Name Sanofi-Synthelabo Inc. and Aventis Pharmaceutical members of the sanofi-aventis Group  
(formerly known as Aventis Pharmaceuticals and Sanofi-Synthelabo)

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code CPT - Copyright/Patent/Trademark (one per page)

16. Specific lobbying issues *Add page to continue specific issues description for this issue*

H.R. 2795, The Patent Reform Act of 2005, and other draft patent reform proposals.  
All provisions

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this issue*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Judy	Cook		N/A
Eddie	Evans		N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Sanofi-aventis is a corporation under French Commercial law, headquartered in Paris, France. Sanofi-Synthelabo and Aventis Pharmaceuticals Inc. are US affiliates and members of the sanofi-aventis Group. The sanofi-aventis Group's interest in this issue is to ensure that any changes to the US patent law does not diminish the intellectual property rights of pharmaceutical manufacturers.

Printed Name and Title \_\_\_\_\_

0000452911



Registrant Name sanofi-aventis group Client Name Sanofi-Synthelabo Inc. and Aventis Pharmaceutical  
 (formerly known as Aventis Pharmaceuticals and Sanofi-Synthelabo)

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the r engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code BUD - Budget/Appropriations (one per page)

16. Specific lobbying issues *Add page to continue specific issues description for this issue*

H.R. 2744 House Agriculture Appropriations, provisions and issues related to the importation of prescription drugs;  
 House Budget Bill, provisions related to the federal government not interfering with negotiations between private insurance plans and pharmaceutical manufacturers on Medicare prescription drugs;  
 Senate Budget Bill, provisions related to the federal government not interfering with negotiations between private insurance plans and pharmaceutical manufacturers on Medicare prescription drugs.

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
 U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Judy	Cook		N/A
Ann	Taylor		N/A
Richard	Hodge		N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Sanofi-aventis is a corporation under French Commercial law, headquartered in Paris, France. Sanofi-Synthelabo and Aventis Pharmaceuticals Inc. are US affiliates and members of the sanofi-aventis Group. The sanofi-aventis Group's interest in this issue is to ensure that Medicare beneficiaries have access to our products and the American public is confident that pharmaceuticals purchased in the US are safe.

Printed Name and Title \_\_\_\_\_

1000452912



Registrant Name sanofi-aventis group Client Name Sanofi-Synthelabo Inc. and Aventis Pharmaceutical  
(formerly known as Aventis Pharmaceuticals and Sanofi-Synthelabo)  
members of the sanofi-aventis Group

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues *Add page to continue specific issues description for this issue*

Proposed Osteoporosis Legislation;  
 S. Res. 56 designating March 2005 as Deep Vein Thrombosis Month in memory of David Bloom;  
 H.R. 3196, The Fair Access to Clinical Trials Act and S. 470, The Fair Access to Clinical Trials Act, all provisions.

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
 U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this issue*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Judy	Cook		N/A
Richard	Hodge		N/A
Eddie	Evans		N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Sanofi-aventis is a corporation under French Commercial law, headquartered in Paris, France. Sanofi-Synthelabo and Aventis Pharmaceuticals Inc. are US affiliates and members of the sanofi-aventis Group. The sanofi-aventis Group's interest in this is to ensure that Medicare beneficiaries will have access to bone mineral screening for osteoporosis, to enhance public awareness of deep vein thrombosis, and to enhance public access to informational clinical trials.

Printed Name and Title \_\_\_\_\_

0000452913



Registrant Name sanofi-aventis group Client Name Sanofi-Synthelabo Inc. and Aventis Pharmaceutical  
(formerly known as Aventis Pharmaceuticals and Sanofi-Synthelabo) members of the sanofi-aventis Group

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code TOR - Torts (one per page)

16. Specific lobbying issues *Add page to continue specific issues description for this issue*

S. 5. Class Action Fairness Act of 2005  
 H.R. 516. Class Action Fairness Act of 2005

17. House(s) of Congress and Federal agencies contacted  Check if None


U.S. Senate  
 U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this issue*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Eddie	Evans		N/A
Ann	Taylor		N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Sanofi-aventis is a corporation under French Commercial law, headquartered in Paris, France. Sanofi-Synthelabo and Aventis Pharmaceuticals Inc. are US affiliates and members of the sanofi-aventis Group. The sanofi-aventis interest in this is to ensure balance and fairness in the US civil justice system.



Printed Name and Title Elise Rhodes, Sr. Director, State Government Affairs

0000452914



0000452915

